Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review.

Pierscianek D, Ahmadipour Y, Oppong MD, Rauschenbach L, Kebir S, Glas M, Sure U, Jabbarli R.

Mol Neurobiol. 2019 Feb 4. doi: 10.1007/s12035-019-1509-2. [Epub ahead of print] Review.

PMID:
30719642
2.

Laboratory biomarkers of delayed cerebral ischemia after subarachnoid hemorrhage: a systematic review.

Jabbarli R, Pierscianek D, Darkwah Oppong M, Sato T, Dammann P, Wrede KH, Kaier K, Köhrmann M, Forsting M, Kleinschnitz C, Roos A, Sure U.

Neurosurg Rev. 2018 Oct 10. doi: 10.1007/s10143-018-1037-y. [Epub ahead of print] Review.

PMID:
30306357
3.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
4.

Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.

Abrigo JM, Fountain DM, Provenzale JM, Law EK, Kwong JS, Hart MG, Tam WWS.

Cochrane Database Syst Rev. 2018 Jan 22;1:CD011551. doi: 10.1002/14651858.CD011551.pub2. Review.

PMID:
29357120
5.

External beam radiation dose escalation for high grade glioma.

Khan L, Soliman H, Sahgal A, Perry J, Xu W, Tsao MN.

Cochrane Database Syst Rev. 2016 Aug 19;(8):CD011475. doi: 10.1002/14651858.CD011475.pub2. Review.

PMID:
27541334
6.

Procarbazine, lomustine and vincristine for recurrent high-grade glioma.

Parasramka S, Talari G, Rosenfeld M, Guo J, Villano JL.

Cochrane Database Syst Rev. 2017 Jul 26;7:CD011773. doi: 10.1002/14651858.CD011773.pub2. Review.

PMID:
28744879
7.

Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma.

Shu C, Wang Q, Yan X, Wang J.

J Mol Neurosci. 2018 Apr;64(4):491-500. doi: 10.1007/s12031-018-1049-7. Epub 2018 Mar 3.

PMID:
29502292
8.

Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.

Kiviniemi A, Gardberg M, Frantzén J, Parkkola R, Vuorinen V, Pesola M, Minn H.

J Neurooncol. 2015 Sep;124(2):237-45. doi: 10.1007/s11060-015-1829-7. Epub 2015 Jun 2.

PMID:
26033547
9.

Association of preoperative levels of selected blood inflammatory markers with prognosis in gliomas.

Auezova R, Ryskeldiev N, Doskaliyev A, Kuanyshev Y, Zhetpisbaev B, Aldiyarova N, Ivanova N, Akshulakov S, Auezova L.

Onco Targets Ther. 2016 Oct 11;9:6111-6117. eCollection 2016.

10.

Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.

Carceller F, Fowkes LA, Khabra K, Moreno L, Saran F, Burford A, Mackay A, Jones DT, Hovestadt V, Marshall LV, Vaidya S, Mandeville H, Jerome N, Bridges LR, Laxton R, Al-Sarraj S, Pfister SM, Leach MO, Pearson AD, Jones C, Koh DM, Zacharoulis S.

J Neurooncol. 2016 Aug;129(1):109-21. doi: 10.1007/s11060-016-2151-8. Epub 2016 May 14.

PMID:
27180091
11.

Comparison between 18f-Dopa and 18f-Fet Pet/Ct in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and our Experience.

Evangelista L, Lea C, Luisa B, Daniele B, Mario C, Pasquale R, Vittorina Z, Giuseppe L.

Curr Radiopharm. 2019 Jan 15. doi: 10.2174/1874471012666190115124536. [Epub ahead of print]

PMID:
30644351
12.

A panel of four cytokines predicts the prognosis of patients with malignant gliomas.

Lin Y, Zhang G, Zhang J, Gao G, Li M, Chen Y, Wang J, Li G, Song SW, Qiu X, Wang Y, Jiang T.

J Neurooncol. 2013 Sep;114(2):199-208. doi: 10.1007/s11060-013-1171-x. Epub 2013 Jun 8.

PMID:
23748572
13.

A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.

Hummel TR, Salloum R, Drissi R, Kumar S, Sobo M, Goldman S, Pai A, Leach J, Lane A, Pruitt D, Sutton M, Chow LM, Grimme L, Doughman R, Backus L, Miles L, Stevenson C, Fouladi M, DeWire M.

J Neurooncol. 2016 Mar;127(1):53-61. doi: 10.1007/s11060-015-2008-6. Epub 2015 Dec 1.

PMID:
26626490
14.

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, Van Gool SW, De Vleeschouwer S.

J Neurooncol. 2013 Oct;115(1):9-17. doi: 10.1007/s11060-013-1201-8. Epub 2013 Jul 4.

PMID:
23824536
15.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

16.

Do Selected Blood Inflammatory Markers Combined with Radiological Features Predict Proliferation Index in Glioma Patients?

Weng Y, Zhang X, Han J, Ouyang L, Liang M, Shi Z, Liu A, Cai W.

World Neurosurg. 2018 Oct;118:e137-e146. doi: 10.1016/j.wneu.2018.06.142. Epub 2018 Jun 26.

PMID:
29959082
17.

Depression and survival of glioma patients: A systematic review and meta-analysis.

Shi C, Lamba N, Zheng LJ, Cote D, Regestein QR, Liu CM, Tran Q, Routh S, Smith TR, Mekary RA, Broekman MLD.

Clin Neurol Neurosurg. 2018 Sep;172:8-19. doi: 10.1016/j.clineuro.2018.06.016. Epub 2018 Jun 18. Review.

18.

Circulatory YKL-40 & NLR: Underestimated Prognostic Indicators in Diffuse Glioma.

Gandhi P, Khare R, VasudevGulwani H, Kaur S.

Int J Mol Cell Med. 2018 Spring;7(2):111-118. doi: 10.22088/IJMCM.BUMS.7.2.111. Epub 2018 Jul 29.

19.

YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC.

Clin Cancer Res. 2006 Oct 1;12(19):5698-704.

20.

Supplemental Content

Support Center